A Wiley Book Series
Series Editors:
Dennis Douroumis, University of Greenwich, UK
Alfred Fahr, Friedrich–Schiller University of Jena, Germany
Jürgen Siepmann, University of Lille, France
Martin Snowden, University of Greenwich, UK
Vladimir Torchilin, Northeastern University, USA
Titles in the Series
Hot‐Melt Extrusion: Pharmaceutical Applications
Edited by Dionysios Douroumis
Drug Delivery Strategies for Poorly Water‐Soluble Drugs
Edited by Dionysios Douroumis and Alfred Fahr
Computational Pharmaceutics: Application of Molecular Modeling in Drug Delivery
Edited by Defang Ouyang and Sean C. Smith
Pulmonary Drug Delivery: Advances and Challenges
Edited by Ali Nokhodchi and Gary P. Martin
Novel Delivery Systems for Transdermal and Intradermal Drug Delivery
Edited by Ryan Donnelly and Raj Singh
Drug Delivery Systems for Tuberculosis Prevention and Treatment
Edited by Anthony J. Hickey
Continuous Manufacturing of Pharmaceuticals
Edited by Peter Kleinebudde, Johannes Khinast, and Jukka Rantanen
Pharmaceutical Quality by Design
Edited by Walkiria S Schlindwein and Mark Gibson
Forthcoming Titles:
Therapeutic Dressings and Wound Healing
Edited by Joshua Boateng
Characterization of Micro‐ and Nanosystems
Edited by Leena Peltonen
Process Analytics for Pharmaceuticals
Edited by Jukka Rantanen, Clare Strachan and Thomas De Beer
Mucosal Drug Delivery
Edited by Rene Holm
Edited by
Nikoletta Fotaki
University of Bath
Claverton Down, UK
Sandra Klein
University of Greifswald
Greifswald, Germany
This edition first published 2020
© 2020 John Wiley & Sons Ltd
All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by law. Advice on how to obtain permission to reuse material from this title is available at http://www.wiley.com/go/permissions.
The right of Nikoletta Fotaki and Sandra Klein to be identified as the authors of the editorial material in this work has been asserted in accordance with law.
Registered Offices
John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA
John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK
Editorial Office
The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK
For details of our global editorial offices, customer services, and more information about Wiley products visit us at www.wiley.com.
Wiley also publishes its books in a variety of electronic formats and by print‐on‐demand. Some content that appears in standard print versions of this book may not be available in other formats.
Limit of Liability/Disclaimer of Warranty
In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of experimental reagents, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each chemical, piece of equipment, reagent, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. While the publisher and authors have used their best efforts in preparing this work, they make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives, written sales materials or promotional statements for this work. The fact that an organization, website, or product is referred to in this work as a citation and/or potential source of further information does not mean that the publisher and authors endorse the information or services the organization, website, or product may provide or recommendations it may make. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for your situation. You should consult with a specialist where appropriate. Further, readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.
Library of Congress Cataloging‐in‐Publication Data
Names: Fotaki, Nikoletta, 1973– editor. | Klein, Sandra, 1970– editor.
Title: In vitro drug release testing of special dosage forms / edited by Nikoletta Fotaki, University of Bath, Claverton Down, Bath, UK, Sandra Klein, University of Greifswald, Greifswald, Germany.
Description: First edition. | Hoboken, NJ : Wiley, 2020. | Series: Advances in pharmaceutical technology | Includes bibliographical references and index.
Identifiers: LCCN 2019024444 (print) | LCCN 2019024445 (ebook) | ISBN 9781118341476 (hardback) | ISBN 9781118675779 (adobe pdf) | ISBN 9781118675830 (epub)
Subjects: LCSH: Solid dosage forms. | Oral medication. | Drugs–Dosage forms.
Classification: LCC RS201.S57 I58 2020 (print) | LCC RS201.S57 (ebook) | DDC 615/.6–dc23
LC record available at https://lccn.loc.gov/2019024444
LC ebook record available at https://lccn.loc.gov/2019024445
Cover design: Wiley
Cover image: © (Background) StudioM1/Getty Images, (Dosage Forms) Courtesy of Sandra Klein
“To our parents for their everlasting love and support”
Aikaterini Avzoti, National and Kapodistrian University of Athens, Greece
Abdulwahab Barakat, PHAST Development GmbH & Co. KG, Konstanz, Germany
Jennifer Dressman, Goethe University, Frankfurt/Main, Germany
Susan D´Souza, Sunovion Pharmaceuticals Inc., Marlborough, MA, USA
Nikoletta Fotaki, Department of Pharmacy and Pharmacology, University of Bath, Bath, UK
Jayachandar Gajendran, PHAST Development GmbH & Co. KG, Konstanz, Germany
Vivian A. Gray, V. A. Gray Consulting, Inc., Hockessin, DE, USA
Alexis Guillot, PHAST Development GmbH & Co. KG, Konstanz, Germany
Murat Kilic, Goethe University, Frankfurt/Main, Germany
Sandra Klein, University of Greifswald, Germany
Johannes Krämer, DISSO GmbH, Homburg, Germany
Annalisa Mercuri, Aptuit, Evotec Company, Verona, Italy
Christos Reppas, National and Kapodistrian University of Athens, Greece
Anne Seidlitz, University of Greifswald, Germany
Christian Simroth‐Loch, University of Greifswald, Germany
Kailas Thakker, Tergus Pharma LLC, Durham NC, USA
Katharina Tietz, University of Greifswald, Greifswald, Germany
Werner Weitschies, University of Greifswald, Greifswald, Germany
Clive G. Wilson, University of Strathclyde, Glasgow, UK
The series Advances in Pharmaceutical Technology covers the principles, methods and technologies that the pharmaceutical industry uses to turn a candidate molecule or new chemical entity into a final drug form and hence a new medicine. The series will explore means of optimizing the therapeutic performance of a drug molecule by designing and manufacturing the best and most innovative new formulations. The processes associated with the testing of new drugs, the key steps involved in the clinical trials process and the most recent approaches utilized in the manufacture of new medicinal products will all be reported. The focus of the series will very much be on new and emerging technologies and the latest methods used in the drug development process.
The topics covered by the series include the following:
Formulation: The manufacture of tablets in all forms (caplets, dispersible, fast‐melting) will be described, as will capsules, suppositories, solutions, suspensions and emulsions, aerosols and sprays, injections, powders, ointments and creams, sustained release and the latest transdermal products. The developments in engineering associated with fluid, powder and solids handling, solubility enhancement, colloidal systems including the stability of emulsions and suspensions will also be reported within the series. The influence of formulation design on the bioavailability of a drug will be discussed and the importance of formulation with respect to the development of an optimal final new medicinal product will be clearly illustrated.
Drug Delivery: The use of various excipients and their role in drug delivery will be reviewed. Among the topics to be reported and discussed will be a critical appraisal of the current range of modified‐release dosage forms currently in use and also those under development. The design and mechanism(s) of controlled release systems including macromolecular drug delivery, microparticulate controlled drug delivery, the delivery of biopharmaceuticals, delivery vehicles created for gastrointestinal tract targeted delivery, transdermal delivery and systems designed specifically for drug delivery to the lung will all be reviewed and critically appraised. Further site‐specific systems used for the delivery of drugs across the blood–brain barrier including dendrimers, hydrogels and new innovative biomaterials will be reported.
Manufacturing: The key elements of the manufacturing steps involved in the production of new medicines will be explored in this series. The importance of crystallization; batch and continuous processing, seeding; and mixing including a description of the key engineering principles relevant to the manufacture of new medicines will all be reviewed and reported. The fundamental processes of quality control including good laboratory practice, good manufacturing practice, Quality by Design, the Deming Cycle, regulatory requirements and the design of appropriate robust statistical sampling procedures for the control of raw materials will all be an integral part of this book series.
An evaluation of the current analytical methods used to determine drug stability, drug dissolution and release, the quantitative identification of impurities, contaminants and adulterants in pharmaceutical materials will be described, as will the production of therapeutic bio‐macromolecules, bacteria, viruses, yeasts, molds, prions and toxins through chemical synthesis and emerging synthetic/molecular biology techniques. The importance of packaging including the compatibility of materials in contact with drug products and their barrier properties will also be explored.
Advances in Pharmaceutical Technology is intended as a comprehensive one‐stop shop for those interested in the development and manufacture of new medicines. The series will appeal to those working in the pharmaceutical and related industries, both large and small, and will also be valuable to those who are studying and learning about the drug development process and the translation of those drugs into new life‐saving and life‐enriching medicines.
In the mid‐1960s people realized that drug dissolution/release has a significant impact on the therapeutic effect of orally administered drugs. Both the United States Food and Drug Administration (FDA) and United States Pharmacopeia introduced dissolution requirements for oral drug products and the first dissolution tests became a quality control (QC) tool to ensure batch‐to‐batch consistency. As a consequence, from the 1970s on, several dissolution test methods were adopted as official QC methods for solid oral dosage forms. In the late 1990s, the increasing number of official dissolution apparatus and dissolution methods in the USP was complemented by the release of various FDA guidances pertaining to in vitro dissolution testing of solid oral dosage forms and its application from a regulatory point of view. Since then, dissolution/drug release testing has expanded considerably, with a variety of apparatus and methods in international pharmacopoeias and numerous international guidances, and nowadays not only addresses questions of QC but also plays an important role in screening of formulations and is also an important tool in proving bioequivalence of different drug products.
In the last decade application of drug release testing has widened to a variety of novel or special dosage forms where it is used for the same purposes. Because of the complexity of specialized dosage forms, a “one fits all” approach is not possible. Moreover, particularly in order to predict the in vivo behavior of such dosage forms, the design of the test methods need to take into account various aspects, including the dosage form design and the conditions at the site of application and/or the site of drug release. Even though a number of special dosage forms are on the market, there is less known about how to design an adequate test method.
In Vitro Drug Release Testing of Special Dosage Forms focuses on the description and discussion of state‐of‐the‐art drug release methodologies to evaluate the key performance of special dosage forms. The book consists of two sections that address both the design and development of compendial and biorelevant dissolution methods. It begins with two chapters devoted to special types of orally administered dosage forms that may require in vitro test setups other than those applied for solid oral dosage forms with immediate or modified release in the gastrointestinal tract. Chapters 3–9 set the focus on compendial and biorelevant performance testing of non‐oral dosage forms and provide a detailed discussion of what is the status of dissolution/drug release methods for this quite heterogenous group of dosage forms, what would be typical requirements for a QC test and what should be the essential features of an in vitro test that can be applied to predict the in vivo performance of these special dosage forms. The last chapter of the book is devoted to regulatory aspects and summarizes the regulatory and compendial documents that relate to in vitro dissolution/drug release testing and discusses the role of method development in setting clinically relevant specifications for novel/special dosage forms.
This book should be the first point of call for anyone starting in the field of in vitro release testing of special dosage forms, as well as those already familiar with this topic, by providing the most recent updates on the field.
We would like to thank all authors for taking the time to share their experiences and contributing a chapter to this book, which allowed us to produce a book that reflects the current status and state‐of‐the‐art thinking in in vitro drug release testing of novel/special dosage forms. Further, we would like to thank the editors at John Wiley & Sons Limited for their continuous support.
Finally, we hope that the information in this book can contribute to efforts in designing and optimizing in vitro methods for determining drug release from special dosage forms.
Nikoletta Fotaki
Sandra Klein